Literature DB >> 2459370

Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans.

W K Bickel1, M L Stitzer, G E Bigelow, I A Liebson, D R Jasinski, R E Johnson.   

Abstract

This study assessed the blockade of hydromorphone challenge effects (cumulative s.c. doses of 0, 6 and 18 mg) during chronic buprenorphine treatment of opioid dependent subjects. Buprenorphine was administered daily via the sublingual route in ascending doses of 2, 4, 8 and 16 mg. Hydromorphone challenges were conducted after 10 to 14 days of chronic administration of each buprenorphine dose and 24 h after the last buprenorphrine dose. Buprenorphrine itself only produced dose-related effects in respiration rate. While subjects were maintained on 2 mg of buprenorphine, the hydromorphone challenge produced dose-related changes in physiological and self-report measures. As the dose of buprenorphine was increased, hydromorphone effects on self-report measures were attenuated to a greater extent than was noted for pupil diameter. The results of this study confirm previous reports of buprenorphine blockade of opioid agonist effects in humans and extent those findings by demonstrating both a buprenorphine dose-effect function and a dissociation between the potency of buprenorphine's opioid blockade for self-report vs. physiological measures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459370

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.

Authors:  Fernanda Magnelli; Lorita Biondi; Roberto Calabria; Angelo Fiore; Eugenio Peluso; Domenico Vonella; Amerigo Giuseppe Rota
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

2.  Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.

Authors:  Patrizia Amato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

Authors:  George E Bigelow; Kenzie L Preston; John Schmittner; Qunming Dong; David R Gastfriend
Journal:  Drug Alcohol Depend       Date:  2011-11-12       Impact factor: 4.492

4.  Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.

Authors:  Azmi F Nasser; Mark K Greenwald; Bradley Vince; Paul J Fudala; Philip Twumasi-Ankrah; Yongzhen Liu; J P Jones; Christian Heidbreder
Journal:  J Clin Psychopharmacol       Date:  2016-02       Impact factor: 3.153

5.  Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?

Authors:  M Pavlic; K Libiseller; P Grubwieser; W Rabl
Journal:  Int J Legal Med       Date:  2005-04-16       Impact factor: 2.686

6.  Examining the factor structure of the Clinical Opiate Withdrawal Scale: A secondary data analysis from the National Drug Abuse Treatment Clinical Trials Network (CTN) 0003.

Authors:  Celestina Barbosa-Leiker; Sterling McPherson; Mary Rose Mamey; G Leonard Burns; Matthew E Layton; John Roll; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2015-04-11       Impact factor: 4.492

7.  Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users.

Authors:  Jermaine D Jones; Maria A Sullivan; Suzanne K Vosburg; Jeanne M Manubay; Shanthi Mogali; Verena Metz; Sandra D Comer
Journal:  Addict Biol       Date:  2014-07-25       Impact factor: 4.280

8.  Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Authors:  Douglas M Ziedonis; Leslie Amass; Marc Steinberg; George Woody; Jonathan Krejci; Jeffrey J Annon; Allan J Cohen; Nancy Waite-O'Brien; Susan M Stine; Dennis McCarty; Malcolm S Reid; Lawrence S Brown; Robert Maslansky; Theresa Winhusen; Dean Babcock; Greg Brigham; Joan Muir; Deborah Orr; Betty J Buchan; Terry Horton; Walter Ling
Journal:  Drug Alcohol Depend       Date:  2008-09-20       Impact factor: 4.492

9.  Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Michelle McKenzie; Josiah D Rich
Journal:  J Opioid Manag       Date:  2012 Jan-Feb

10.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.